Cargando…

Systemic immune-inflammation index and prognosis of advanced non-small cell lung cancer

Detalles Bibliográficos
Autor principal:	Alifano, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327370/ https://www.ncbi.nlm.nih.gov/pubmed/32617287 http://dx.doi.org/10.21037/atm.2020.03.174

Ejemplares similares

Clinical impact of the systemic immune-inflammation index in non-small cell lung cancer patients
por: Shoji, Fumihiro
Publicado: (2020)

Systemic Inflammation and Lung Cancer: Is It a Real Paradigm? Prognostic Value of Inflammatory Indexes in Patients with Resected Non-Small-Cell Lung Cancer
por: Mazzella, Antonio, et al.
Publicado: (2023)

The Lung Immune Prognostic Index (LIPI) stratifies prognostic groups in advanced non-small cell lung cancer (NSCLC) patients
por: Aldea, Mihaela, et al.
Publicado: (2020)

Preoperative systemic immune-inflammation index predicts prognosis and guides clinical treatment in patients with non-small cell lung cancer
por: Yan, Xue, et al.
Publicado: (2020)

The inflammatory burden index is a superior systemic inflammation biomarker for the prognosis of non‐small cell lung cancer
por: Xie, Hailun, et al.
Publicado: (2023)

Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer
por: Mountzios, G., et al.
Publicado: (2021)

Systemic Inflammation, Nutritional Status and Tumor Immune Microenvironment Determine Outcome of Resected Non-Small Cell Lung Cancer
por: Alifano, Marco, et al.
Publicado: (2014)

A Low Advanced Lung Cancer Inflammation Index Predicts a Poor Prognosis in Patients With Metastatic Non–Small Cell Lung Cancer
por: Lu, Ping, et al.
Publicado: (2022)

Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer
por: Zhang, Ke, et al.
Publicado: (2019)

Prognostic value of LIPC in non-small cell lung carcinoma
por: Alifano, Marco, et al.
Publicado: (2013)

New Therapeutic Strategies for Lung Cancer
por: Icard, Philippe, et al.
Publicado: (2021)

Immunotherapy in non-small cell lung cancer: advancements and challenges
por: Zhou, Fei, et al.
Publicado: (2021)

Exploring the implications of modified advanced lung cancer inflammation index on outcomes in patients with advanced non-small cell lung cancer
por: Mahajan, Abhishek, et al.
Publicado: (2023)

Systemic immune-inflammation index for predicting prognosis of colorectal cancer
por: Chen, Jian-Hui, et al.
Publicado: (2017)

Significance of NLDA, the commixed index of inflammation, immune responses, hemostasis, and nutrition, for predicting metastatic non-small cell lung cancer prognosis and metastases
por: Sun, Wen-wen, et al.
Publicado: (2017)

Is smoking history the truly best biomarker for immune checkpoint inhibitor treatment in advanced non-small cell lung cancer?
por: Pirker, Robert
Publicado: (2018)

Diagnosis and treatment of non-small cell lung cancer: current advances and challenges
por: Diebels, Ian, et al.
Publicado: (2022)

Systemic immune-inflammation index is a stage-dependent prognostic factor in patients with operable non-small cell lung cancer
por: Fu, Fangqiu, et al.
Publicado: (2021)

High systemic immune-inflammation index predicts poor prognosis in advanced lung adenocarcinoma patients treated with EGFR-TKIs
por: Deng, Chao, et al.
Publicado: (2019)

TTF-1 and immune checkpoint therapy in non-small cell lung cancer
por: Gumbleton, Matthew, et al.
Publicado: (2023)

Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab‐treated patients with advanced non–small cell lung cancer
por: Shiroyama, Takayuki, et al.
Publicado: (2017)

Advancements in next-generation sequencing for diagnosis and treatment of non-small-cell lung cancer
por: Lu, Ying-Qiang, et al.
Publicado: (2017)

Expert consensus on perioperative immunotherapy for locally advanced non-small cell lung cancer
por: Lim, Jeong Uk, et al.
Publicado: (2021)

Cisplatin or carboplatin for advanced non-small cell lung cancer: does it really matter?
por: Kesireddy, Meghana, et al.
Publicado: (2021)

Anatomic lung resection after immune checkpoint inhibitors for initially unresectable advanced-staged non-small cell lung cancer: a retrospective cohort analysis
por: Etienne, Harry, et al.
Publicado: (2023)

Cachexia Index in Advanced Non-Small-Cell Lung Cancer Patients
por: Jafri, Syed Hasan Raza, et al.
Publicado: (2015)

Pre-radiotherapy systemic immune inflammation index associated with overall survival in patients with advanced EGFR mutant non-small cell lung cancer receiving thoracic radiotherapy
por: Chen, Dujuan, et al.
Publicado: (2022)

The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab
por: Matsubara, Taichi, et al.
Publicado: (2020)

Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer
por: Tong, Yu-Suo, et al.
Publicado: (2017)

Systemic immune‐inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected non‐small cell lung cancer
por: Guo, Wei, et al.
Publicado: (2019)

Re-administration of immune checkpoint inhibitors for patients with non-small cell lung cancer
por: Hakozaki, Taiki
Publicado: (2022)

Immune checkpoint inhibitors for patients with gene-rearranged non-small cell lung cancer
por: Uehara, Yuji, et al.
Publicado: (2022)

Establishment and Validation of Nomogram Model Integrated With Inflammation-Based Factors for the Prognosis of Advanced Non-Small Cell Lung Cancer
por: Huang, Zhiliang, et al.
Publicado: (2020)

Tepotinib for advanced non-small-cell lung cancer with MET exon 14 skipping mutations
por: Błaszkowska, M., et al.
Publicado: (2022)

Efficacy of second-line chemotherapy after immunotherapy in advanced non-small cell lung cancer
por: Hirata, Tsuyoshi, et al.
Publicado: (2023)

Surgery for Non-Small Cell Lung Cancer in the Personalized Therapy Era
por: Chiappetta, Marco, et al.
Publicado: (2023)

The Relationship Between Systemic Immune Inflammatory Index and Prognosis of Patients With Non-Small Cell Lung Cancer: A Meta-Analysis and Systematic Review
por: Huang, Wei, et al.
Publicado: (2022)

Systemic immune-inflammation index in germ-cell tumours: search for a biological prognostic biomarker
por: Albany, Costantine
Publicado: (2018)

Prognostic Impact of the Advanced Lung Cancer Inflammation Index (ALI) in Metastatic Non-Small Cell Lung Cancer Treated with First Line Chemotherapy
por: Chantharakhit, Chaichana, et al.
Publicado: (2021)

The advanced lung cancer inflammation index predicts outcomes of patients with non-small cell lung cancer following video-assisted thoracic surgery
por: Han, Zhaohui, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kbusdni603v8niqnq8kac42qqg